As BRCA1 carriers are more likely to develop ER-negative disease, SNPs associated with this subtype will be more informative in models to predict overall breast cancer risk in these women, whereas SNPs associated with ER-positive disease will be more useful in BRCA2 carriers. This evidence concerns the gene BRCA1 and breast carcinoma.